ORG 20091

Drug Profile

ORG 20091

Latest Information Update: 08 Jan 2001

Price : $50

At a glance

  • Originator Organon
  • Class Anxiolytics; Nootropics; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Muscarinic M1 receptor agonists; Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Anxiety disorders; Cognition disorders; Major depressive disorder

Most Recent Events

  • 08 Jan 2001 Discontinued-Preclinical for Cognition disorders in Netherlands (Unknown route)
  • 08 Jan 2001 Discontinued-Preclinical for Anxiety disorders in Netherlands (Unknown route)
  • 08 Jan 2001 Discontinued-Preclinical for Depression in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top